Action DARE DARÉ BIOSCIENCE, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Daré Bioscience, Inc.

Actions

DARE

US23666P1012

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 01/05/2024 		Varia. 5j. Varia. 1 janv.
0,3299 USD +7,28% Graphique intraday de Daré Bioscience, Inc. +15,35% +6,76%
30/04 Daré Bioscience, Inc. conclut une opération de monétisation des redevances avec XOMA (US) LLC CI
30/04 XOMA Corporation (NasdaqGM:XOMA) a complété l'acquisition de trois actifs de première catégorie de Daré Bioscience, Inc. (NasdaqCM:DARE) pour 22 millions de dollars. CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
Daré Bioscience, Inc. Closes Royalty Monetization Transaction with XOMA (US) LLC
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Daré Bioscience, Inc. Announces Executive Changes
Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned
Daré Bioscience Announces Executive Team and Board of Directors Changes
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action DARE
  4. Actualités Daré Bioscience, Inc.
  5. Autres langues